Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Cash & Current Investments: 2023-2024

Historic Cash & Current Investments for Compass Therapeutics (CMPX) over the last 2 years, with Dec 2024 value amounting to $127.3 million.

  • Compass Therapeutics' Cash & Current Investments rose 62.14% to $220.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $562.5 million, marking a year-over-year decrease of 7.90%. This contributed to the annual value of $127.3 million for FY2024, which is 16.51% down from last year.
  • Compass Therapeutics' Cash & Current Investments amounted to $127.3 million in FY2024, which was down 16.51% from $152.5 million recorded in FY2023.
  • In the past 5 years, Compass Therapeutics' Cash & Current Investments ranged from a high of $152.5 million in FY2023 and a low of $127.3 million during FY2024.
  • Its 2-year average for Cash & Current Investments is $139.9 million, with a median of $139.9 million in 2023.
  • Data for Compass Therapeutics' Cash & Current Investments shows a maximum YoY declined of 16.51% (in 2024) over the last 5 years.
  • Yearly analysis of 2 years shows Compass Therapeutics' Cash & Current Investments stood at $152.5 million in 2023, then dropped by 16.51% to $127.3 million in 2024.